NEUROLOGIE PRO PRAXI / Neurol. praxi. 2023;24(5):346-352 / www.neurologiepropraxi.cz 352 HLAVNÍ TÉMA Precizní neuroonkologie – realita a perspektivy mized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009;27:1268-74. 37. Van Den Bent M, Eoli M, Sepulveda JM, et al. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux‑M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol. 2020;22:684-93. 38. Wen PY, Stein A, van den Bent M, et al. Dabrafenib plus trametinib in patients with BRAFV600E‑mutant low‑grade and high‑grade glioma (ROAR): a multicentre, open‑label, single‑arm, phase 2, basket trial. Lancet Oncol. 2022;23:53-64. 39. Weller M, Butowski N, Tran DD, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII‑expressing glioblastoma (ACT IV): a randomised, double‑blind, international phase 3 trial. Lancet Oncol. 2017;18:1373-85. 40. Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18:170-86. 41. Wick A, Bähr O, Schuler M, et al. Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. Clin Cancer Res. 2021;27:2723-33. 42. Wick W, Dettmer S, Berberich A, et al. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non‑MGMT hypermethylated glioblastoma. Neuro Oncol. 2019;21:95-105. 43. Wick A, Kessler T, Platten M, et al. Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT growth in combination with temozolomide. Neuro Oncol. 2019;21:189-200. 44. Yamashita AS, da Costa Rosa M, Borodovsky A, et al. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma promoter methylated malignant astrocytoma. Neuro Oncol. 2020;22: 1162-72. 45. Yip S, Butterfield YS, Morozova O, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol. 2012;226:7-16. PŘEDNÁŠKY Význam studie PEARL pro klinickou praxi – MUDr. Jolana Marková, FEAN Medication overuse headache a role anti-CGRP – MUDr. Petra Migaľová Lékové interakce migréna a RS – update – PharmDr. Josef Suchopár Výhody exibility podání fremanezumabu u našich pacientů – MUDr. Monika Záhumenská ODBORNÝ GARANT MUDr. Jolana Marková, FEAN Neurologická klinika, Fakultní Thomayerova nemocnice v Praze PARTNER POČET KREDITŮ 2 Registrace ZDARMA TERMÍN prosinec 2022 až listopad 2023 dostupný na online.solen.cz On-line kurz pro praktické neurology Trendy v léčbě migrény 3 2022 ON LINE KURZ
RkJQdWJsaXNoZXIy NDA4Mjc=